Primary Aldosteronism

A call to action for screening and optimization of laboratory screening methods

Tuesday, July 26
12:45 – 1:45 p.m.
Exhibit Hall Theater 3
Supported by DiaSorin

Overview

Primary aldosteronism (PA) is a significant public health condition recognized as a major subset within the hypertensive population. Unlike the majority of hypertension, its singular pathophysiologic basis enables precise and highly effective treatment options. Diagnostic challenges that plague providers include an under-recognition of PA prevalence and concern regarding testing conditions surrounding aldosterone and renin assessments.

Outcomes

After attending this session, participants will be able to:

  • Understand the clinical impact of primary aldosteronism.
  • Recognize the need for increased screening in at-risk populations.
  • Gain insight into best practices for laboratories converting from plasma renin activity to direct renin concentration.

Moderator

Andrea Diebel
Product Manager
DiaSorin


Speakers

Jonathan S. Williams, MD, MMSc
Associate Professor of Medicine - Harvard Medical School
Director, Cardiovascular Endocrine Human Genetics
Research Program - Brigham and Women’s Hospital


Alison Woodworth, PhD, DABCC, FAACC
Professor, Clinical Title Series
Medical Director, Clinical Chemistry and Point of Care Testing